Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia

Blood

Volumn 108, Issue 3, 2006, Pages 1001-1006

  Koller, Charles ^b   Bekele, B Nebiyou ^b   Zhou, Xian ^b   Park, Charles ^b   Estrov, Zeev ^b   O'Brien, Susan ^b   Keating, Michael ^b   Jilani, Iman ^b   Giles, Francis J ^b   Kantarjian, Hagop M ^b   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN HEAVY CHAIN; THROMBOPOIETIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 33746594514     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-2110     Document Type: Article

References (36)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
2. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103:1202-1210.
3. Ferrarini M, Chiorazzi N. Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. Semin Hematol. 2004;41:207-223.
4. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996;22:439-447.
5. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181-186.
6. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115:854-861.
7. Morabito F, Mangiola M, Oliva B, et al. Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. Leuk Res. 2001;25:927-932.
8. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
10. Stilgenbauer S, Bullinger L, Lichter P, et al. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 2002;16:993-1007.
11. Messmer BT, Albesiano E, Messmer D, Chiorazzi N. The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. Blood. 2004;103:3490-3495.
12. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
13. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
14. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
15. Heits F, Katschinshki DM, Wilmsen U, Wiedemann GJ, Jelkmann W. Serum thrombopoietin and interleukin 6 concentrations in tumor patients and response to chemotherapy-induced thrombocytopenia. Eur J Haematol. 1997;59:53-58.
16. Tafuri A, Lemoli R, Petrucci M, et al. Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. Exper Hematol. 1999;27:1255-1263.
17. Oda A, Miyakawa Y, Druker B, et al. Thrombopoietin-induced signal transduction and potentiation of platelet activation. Thromb Haemostas. 1999;82:377-384.
18. Wendling F. Thrombopoientin: its role from early heatopoiesis to platelet production. Haematologica. 1999;84:158-166.
19. National Center for Biotechnology Information. IgBLAST. http://www.ncbi.nlm.nih.gov/igblast/. Accessed December 2004.
20. The International ImMunoGeneTics Information System. IMGT. http://imgt.cines.fr. Accessed December 2004.
21. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, IA: Iowa State University Press; 1980.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc. 1958;53:457-481.
23. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II, analysis and examples. Br J Cancer. 1977;35:1-39.
24. Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187-220.
25. Therneau TM, Grambsch PM. Modeling Survival Data. New York, NY: Springer; 2000.
26. Thall PF, Estey EH. Graphical methods for evaluating covariate effects in the Cox model. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. New York, NY: Marcel Dekker; 2001:411-432.
27. SAS Institute. SAS/STAT Users Guide. Version 8. Cary, NC: SAS Institute; 1999.
28. Breiman L, Friedman JH, Olsen RA, Stone CJ. Classification and Regression Trees. Monterey, CA: Wadsworth and Brooks/Cole; 1984.
29. Efron B, Tibshirani RJ. An introduction to the Bootstrap. Boca Raton, FL: Chapman & Hall; 1993:202-218.
30. Hilsenbeck SG, Clark GM. Practical p-value adjustment for optimally selected cutpoints. Stat Med. 1996;15:103-112.
31. Cotton JM, Hong Y, Hawe E, et al. Rise of circulating thrombopoietin following cardiothoracic surgery is potentiated in patients with coronary atherosclerosis: correlation with a preceding increase in levels of interleukin-6. Thromb Haemost. 2003;89:538-543.
32. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
33. Valganon M, Giraldo P, Agirre X, et al. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. Br J Haematol. 2005;129:53-59.
34. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25:80-97.
35. Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood. 2002;100:2260-2262.
36. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J, ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004;76:205-213.